Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Bevacizumab in Advanced Hepatocellular Carcinoma
NCT00867321Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2009
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Cancer and Leukemia Group B. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00867321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867321.